18th Mar 2015 07:59
LONDON (Alliance News) - Imperial Innovations Group PLC said Wednesday its portfolio company Cell Medica Ltd's lead cancer immunotherapy product CMD-003 has been granted an orphan drug designation by the US Food and Drug Administration.
This designation qualified the company for some benefits, including seven years of market exclusivity after marketing approval. The designation was granted for the treatment of Epstein-Barr Virus positive non-Hodgkin lymphomas.
Cell Medica also began the treatment of the first patient in its phase II trial into the safety and efficacy of CMD-003 for aggressive extranodal NK/T cell lymphoma in patients whose treatment with other therapies has been unsuccessful.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Imperial Innovations Group